Common names: Osage copperhead, central copperhead.[1]
Agkistrodon contortrix phaeogaster was formerly a venomous pit viper subspecies found in the central region of the United States. However, recent taxonomic changes do not recognize the Osage copperhead (A. c. phaeogaster) as a valid taxon.
The Osage copperhead (Agkistrodon contortrix phaeogaster) was once classified as a subspecies of the copperhead (Agkistrodon contortrix). However, DNA based studies published in 2008 and 2015, revealed no significant genetic difference between the Osage copperhead (Agkistrodon contortrix phaeogaster), the southern copperhead, (Agkistrodon contortrix contortrix), and the northern copperhead (Agkistrodon contortrix mokasen). The three subspecies were synonymized and elevated to one species, with the oldest published name, Agkistrodon contortrix, having priority. The resulting taxonomy does not recognizes the Osage copperhead (Agkistrodon contortrix phaeogaster) as a valid taxon.[2] [3] Several subsequent reviews and species accounts have followed and supported the revised taxonomy.[4] [5] [6] Information on this snake can be found in the Agkistrodon contortrix article.
Gloyd and Conant (1990) gives maximum total lengths of 990 to 723 mm for males and females, respectively, while mentioning that other sources give a maximum total length for this subspecies of 1,016 mm regardless of sex.[1]
The color pattern is similar to that of A. c. mokasen, except that the dark bands are in sharper contrast to the lighter ground color, and with no smaller dark spots between them.[7]
Found in the United States in eastern Kansas, extreme southeastern Nebraska and a large part of Missouri.[1] The type locality given is "10 miles south of McLouth, Jefferson County, Kansas."
The venom of Agkistrodon contortrix phaeogaster is similar to the venoms produced by other species of the Agkistrodon genus. The exact ratio of toxins to each other varies among species and gender, as does the overall potency of the venom (the ratio of active toxins to other constituents of the venom). The venom is most potent between the late-spring and mid-summer months, this rise in toxicity commences 2–3 weeks prior to reaching peak toxicity. While the initial reduction of potency occurs over approximately one month, the snake's venom remains slightly more toxic throughout the late-summer months until beginning a slow descent to reach its original toxicity by mid-fall.
The bite of the Osage copperhead is considered a medical emergency and the victim should be brought to a hospital immediately for the best prognosis (an ambulance should be called if the victim is alone, as driving is highly dangerous after an envenomation).
The effects of the toxic venom present with a predictable course of symptoms until treatment is received. Immediate and severe pain, oozing of blood from the fang punctures, considerable edema, epistaxis, bleeding of the gums, marked hematuria, general petechiae, shock, renal failure, and local necrosis. These effects are attributed to the various haemotoxins and necrotoxins contained in the venom. Many other toxins are present in the venom in small quantities and are not clinically significant due to their extremely low concentrations.
CroFab antivenin has been used successfully to treat Osage copperhead bites, although a lack of complete cross-tolerance requires careful administration and close supervision during the full course of treatment to ensure that the lowest effective dose is administered (a lower dose would not fully treat the envenomation, and a higher dose may be particularly dangerous to children, the elderly, and infirm adults). Not uncommonly, opiate/opioid narcotic analgesics (ex. morphine, fentanyl), muscle relaxerss (ex. diazepam, tizanidine, orphenadrine), and broad-spectrum antibiotics are administered. A few days' supply of weaker analgesics and muscle relaxers may be prescribed for the patient to control pain after he or she returns home as the pain resolves completely within one to three days. Patients also receive a prescription for an intensive antibiotic therapy, which much be taken until the supplies are depleted, giving the drug enough time to fully treat any opportunistic infections resulting from the bite wounds or other transmission methods which the victim's weakened immune system cannot defend against. Failing to take the antibiotics until the prescription is depleted can cause the bacteria to "rebound" in a new form, possessing a greater resistance to antibiotics (MRSA developed through this process).
CroFab antivenin is effective in treating A.C. phaeogaster bites, but it may cause severe anaphylactic shock and should not be used in any individuals allergic to anything contained within the formula, unless the allergy is limited to nonlethal grievances such as rashes and itching. One other exception to this occurs when the envenomation is so severe that the victims' doctors determine this risk of death from envenomation outweighs the risk of inducing anaphylaxis in a critically ill patient. A major shortage of CroFab existed in the U.S., and the vials which were available were exorbitantly priced, leading many doctors to negate the use of the antivenin in many patients whose bite resulted in extreme suffering. However, they did not present any life-threatening symptoms (in these situations, palliative care and symptomatic/supportive treatment approaches were used, instead).